Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.78 |
| ▸ | POLB | P06746 | 1/20 | 0.78 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.72 |
| ▸ | JAK2 | O60674 | 1/20 | 0.61 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.45 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29565312 | 1.00 | MAPT (0.78) | MAPTMAPK1POLBL3MBTL1JAK2 | |
| SCHEMBL30776873 | 1.00 | MAPT (0.78) | MAPTMAPK1POLBL3MBTL1JAK2 | |
| SCHEMBL29141097 | 0.90 | MAPT (0.69) | MAPTMAPK1POLBL3MBTL1JAK2 | |
| SCHEMBL31717653 | 0.87 | MAPK1 (0.78) | MAPTMAPK1POLBL3MBTL1JAK2 | |
| SCHEMBL21811853 | 0.87 | MAPK1 (0.72) | MAPTMAPK1POLBL3MBTL1JAK2 | |
| SCHEMBL30509795 | 0.87 | MAPK1 (0.72) | MAPTMAPK1POLBL3MBTL1JAK2 | |
| SCHEMBL23675301 | 0.81 | MAPT (0.51) | MAPTMAPK1POLBL3MBTL1MEN1 | |
| SCHEMBL23675118 | 0.81 | MAPT (0.79) | MAPTMAPK1POLBL3MBTL1JAK2 | |
| SCHEMBL23675257 | 0.81 | MAPT (0.61) | MAPTL3MBTL1AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL29868880 | 0.81 | MAPT (0.79) | MAPTMAPK1POLBL3MBTL1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240262820-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | MYOFORTE THERAPEUTICS, INC. | 2024-08-08 | — | — | US | disclosed |
| US-11891389-B2 | PGDH inhibitors and methods of making and using | MYOFORTE THERAPEUTICS, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| US-20230390274-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | MYOFORTE THERAPEUTICS, INC. | 2023-12-07 | — | — | US | disclosed |
| EP-4228650-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | Epirium Bio Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4093385-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | Myoforte Therapeutics Inc. (US) | 2022-11-30 | — | — | EP | disclosed |
| US-11345702-B1 | PGDH inhibitors and methods of making and using | MYOFORTE THERAPEUTICS, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2022082009-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | EPIRIUM BIO INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2021151014-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | MYOFORTE THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891389-B2 | PGDH inhibitors and methods of making and using | HPGD, HPGDS, PTGS1 | MAPT 4693/4885MAPK1 3440/4885POLB 1102/4885 |
| US-20240262820-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | HPGD, HPGDS, PTGS1 | MAPT 4762/4885MAPK1 3772/4885POLB 926/4885 |
| US-20230390274-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | HPGD, HPGDS, GCDH | MAPT 4312/4885MAPK1 4510/4885POLB 1449/4885 |
| US-11345702-B1 | PGDH inhibitors and methods of making and using | HPGD, HPGDS, PTGS1 | MAPT 4693/4885MAPK1 3440/4885POLB 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.